BCL-2 family regulation by the 20S proteasome inhibitor bortezomib

被引：129

作者：

Fennell, D. A. ^{[1
]}

Chacko, A. ^{[1
]}

Mutti, L. ^{[2
]}

机构：

[1] Queens Univ Belfast, Thorac Oncol Res Grp, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland

[2] Med Gen Lab Oncol Clin, Vercelli, Italy

来源：

ONCOGENE | 2008年 / 27卷 / 09期

关键词：

mitochondria; proteasome; BAX; BAK; BIM; NOXA;

D O I：

10.1038/sj.onc.1210744

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Bortezomib (Velcade, PS341) was licensed in 2003 as a first-in-class 20S proteasome inhibitor indicated for treatment of multiple myeloma, and is currently being evaluated clinically in a range of solid tumours. The mechanisms underlying its cancer cell toxicity are complex. A growing body of evidence suggests proteasome inhibition-dependent regulation of the BCL-2 family is a critical requirement. In particular, the stabilization of BH3-only proteins BIK, NOXA and BIM, appear to be essential for effecting BAX- and BAK-dependent cell death. These mechanisms are reviewed and the implications for favourable novel drug interactions are highlighted.

引用

页码：1189 / 1197

页数：9

共 50 条

[21] Effects of the 26S proteasome inhibitor, bortezomib, on BCL-2 in small cell lung cancer: Implications for SWOG-0327.
Mortenson, MM
Schlieman, MG
Virudachalam, S
Lara, PN
Gandara, DG
Davies, AM
Bold, RJ
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 849S - 849S
[22] Identify the mechanisms of resistance to bortezomib by sequencing the genes of the subunits beta of the proteasome 20s
Fouquet, Guillemette
Leleu, Xavier
HEMATOLOGIE, 2012, 18 (06): : 315 - 315
[23] Insight into Inhibitor Binding in the Eukaryotic Proteasome: Computations of the 20S CP
Hodoscek, Milan
Elghobashi-Meinhardt, Nadia
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (12)
[24] Targeting BCL-2 overexpression in various human malignancies through NF-κB inhibition by the proteasome inhibitor bortezomib
Fahy, BN
Schlieman, MG
Mortenson, MM
Virudachalam, S
Bold, RJ
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (01) : 46 - 54
[25] Targeting BCL-2 overexpression in various human malignancies through NF-κB inhibition by the proteasome inhibitor bortezomib
Bridget N. Fahy
Michael G. Schlieman
Melinda M. Mortenson
Subbulakshmi Virudachalam
Richard J. Bold
Cancer Chemotherapy and Pharmacology, 2005, 56 : 46 - 54
[26] Regulation of osteoblastic differentiation by the proteasome inhibitor bortezomib
Uyama, Maki
Sato, Mari M.
Kawanami, Masamitsu
Tamura, Masato
GENES TO CELLS, 2012, 17 (07) : 548 - 558
[27] The Bcl-2 family and cell death regulation
Newton, K
Strasser, A
CURRENT OPINION IN GENETICS & DEVELOPMENT, 1998, 8 (01) : 68 - 75
[28] VDAC regulation by the Bcl-2 family of proteins
Tsujimoto, Y
Shimizu, S
CELL DEATH AND DIFFERENTIATION, 2000, 7 (12): : 1174 - 1181
[29] VDAC regulation by the Bcl-2 family of proteins
Y Tsujimoto
S Shimizu
Cell Death & Differentiation, 2000, 7 : 1174 - 1181
[30] The 20S proteasome of Streptomyces coelicolor
Nagy, I
Tamura, T
Vanderleyden, J
Baumeister, W
De Mot, R
JOURNAL OF BACTERIOLOGY, 1998, 180 (20) : 5448 - 5453

← 1 2 3 4 5 →